Cryoballoon ablation for atrial fibrillation: Effects on neuromodulation

Alvise Del Monte¹, Luigi Pannone¹, Antonio Bisignani¹, Thiago G. Osório¹, Saverio Iacopino¹,², Gian-Battista Chierchia¹* and Carlo de Asmundis¹†

¹Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel - Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium, ²Arrhythmology Department, Maria Cecilia Hospital, Colignola, Italy

Pulmonary vein isolation (PVI) represents the mainstay of atrial fibrillation (AF) ablation, and PVI with cryoballoon catheter (CB) ablation (CB-A) has proven to be as effective and safe as radiofrequency ablation (RF-A). Although AF is initiated by triggers arising from the pulmonary veins (PV) and non-PV foci, the intrinsic cardiac nervous system (ICNS) plays a significant role in the induction and maintenance of AF. The ICNS is an epicardial neural system composed of ganglionated plexi (GPs) and a complex network of interconnecting neurons. In the left atrium, the major GPs are located in proximity to the PV-left atrial junction. Vagal reactions have been described as markers of autonomic modulation during PVI with both RF-A and CB-A. The occurrence of neuromodulation during PVI with CB-A may be explained by both the anatomical relationship between the GPs and the PVs and the characteristics of the CB. Due to the CB/PV size mismatch, the CB creates a wide ablation area that extends from the PV ostium toward the antrum, possibly including the GPs. Although targeted GPs ablation, as a supplemental strategy to PVI, has been associated with a better AF outcome in patients undergoing RF-A, the additional clinical benefit of neuromodulation during PVI with CB-A remains a matter of debate. In this review, we provide an overview of the anatomy of the ICNS, the relationship between the ICNS and AF pathophysiology, and the current evidence on the clinical relevance of neuromodulation during PVI with CB-A.

KEYWORDS
cryoballoon ablation, atrial fibrillation, cardiac autonomic nervous system, autonomic denervation, ganglionated plexi, neuromodulation

Introduction

Atrial fibrillation (AF) is known to be initiated by arrhythmogenic triggers originating from pulmonary vein (PV) and non-PV foci (1–3). According to the current guidelines, electrical isolation of the pulmonary veins (PVI) remains the cornerstone of AF ablation (4), and PVI with cryoballoon catheter (CB) ablation (CB-A) has been proven to be non-inferior to radiofrequency (RF) ablation (RF-A) with regard to safety and clinical outcomes (5).
Preclinical and clinical studies have shown that the intrinsic cardiac nervous system (ICNS) plays a crucial role in the induction and maintenance of AF through the regulation of different components of atrial cellular electrophysiology (6–9). The ICNS is an epicardial neural system composed of ganglionated plexi (GPs) and a complex network of interconnecting neurons that regulate cardiac electrical and mechanical functions on a beat-to-beat basis (10). In the atria, the major GPs are located in epicardial fat pads in close proximity to the PVs. Histological examination of the human heart has demonstrated that autonomic nerve density is mainly represented in the anterosuperior segments of both superior PVs and inferior segments of both inferior PVs, within 5 mm of the PV-left atrial (LA) junction, and in the epicardium (11).

The evidence of a vagal reflex, as a marker of GPs modification, during PVI with RF-A has posed the basis for the investigation of the role of neuromodulation on AF outcome. Several observational and few randomized studies have suggested that GPs ablation, as a supplemental strategy to PVI, might be associated with an additional clinical benefit in patients undergoing RF-A for both paroxysmal and persistent AF (12–14). Vagal reactions have also been reported during PVI with CB-A (15), especially during ablation of the left superior PV (16). The rationale behind neuromodulation during CB-A of AF is represented by both the close anatomical relationship between the GPs and the PVs, and the characteristics of the CB. Due to the size mismatch between the CB and the PV, the balloon is often in contact with atrial tissue distant from the PV orifice (17, 18), creating a large antral ablation area that can include the GPs (19). Although sometimes considered as part of the therapeutic effect (20), the clinical significance of GPs ablation in the context of CB-A for AF remains to be fully elucidated.

The aim of this review is to provide an overview of the anatomical basis, pathophysiological principles, and clinical significance of neuromodulation in the context of CB-A for AF.

Anatomy of the cardiac autonomic nervous system: Relevant concepts for neuromodulation

The autonomic innervation of the heart relies on both sympathetic and parasympathetic fibers (21) and it can be anatomically divided into the extrinsic cardiac nervous system (ECNS) and the ICNS.

The ECNS consists of the nuclei in the brain stem, the ganglia along the cervical and thoracic segments of the spinal cord, and their axons that converge to the heart. Preganglionic sympathetic neurons arise from the spinal cord, synapse with the second sympathetic neurons in the paravertebral ganglia (mainly the cervical and stellate ganglia), and emit postganglionic axons that innervate the cardiomyocytes. Preganglionic parasympathetic neurons are located primarily in the dorsal vagus nerve and the nucleus ambiguus, and synapse with the second parasympathetic neurons, which lie in the epicardial clusters of autonomic ganglia, known as GPs (22, 23).

The ICNS is a complex epicardial neural network composed of the epicardial GPs, afferent and efferent nerve axons, and interconnecting neurons. GPs contain both sympathetic and parasympathetic elements, as well as multiple neuropeptides and neuromodulators, including calcitonin gene-related peptide, vasoactive intestinal polypeptide, substance P, and nitric oxide (24). The function of GPs is not only to modulate the autonomic interplay between the ECNS and the ICNS as “integration-centers” but also to independently regulate cardiac electrical and mechanical functions through the transduction of local signals (25). Epicardial ganglia in the human heart are present in both the atria and the ventricles and range in size from those containing a few neurons to large ganglia that measure up to 1 mm, containing over 200 neurons (26).

The anatomical localization of the atrial GPs represents a matter of scientific interest, especially for the identification of specific targets for arrhythmia treatment. The most commonly used classification of the atrial GPs in experimental and clinical studies is the one described by Armour et al. (26). The authors identified five major atrial GPs: (1) the superior right atrial GP, located on the posterosuperior surface of the right atrium (RA) adjacent to the junction of the superior vena cava (SVC) and the RA; (2) the superior left atrial GP, located on the posterosuperior surface of the LA between the PVs; (3) the posterior right atrial GP, located on the posterior surface of the RA, adjacent to the interatrial groove; (4) the posteromedial left atrial GP, located on the posteroomedial surface of the LA; and (5) the posterolateral left atrial GP, located on the posterolateral surface of the LA base. The septal extensions of the posterior right atrial and posteromedial left atrial GPs form the interatrial septal GP.

For easier communication between electrophysiologists, the GPs have been renamed according to their relationship with the PVs (27): (1) the superior left GP (SLGP), located on the roof of the LA, 1–2 cm medial to the left superior PV; (2) the anterior right GP (ARGP), located anterior to the right superior PV; (3) the inferior left GP (ILGP); and (4) the inferior right GP (IRGP), situated at the inferior aspect of the posterior wall of the LA, 1–3 cm below the inferior PVs (Figure 1).

The concept of GPs as a grouping of ganglia in different epicardial sites has been challenged by later studies on whole heart preparations, which demonstrated that the GPs are densely interconnected by thinner nerves and should be considered as distinctive ganglionated areas of a single continuous cardiac ganglionated nerve plexus, from which intrinsic nerves extend to distinct cardiac regions (28). Both the ganglia and their connections were defined as ganglionated subplexi (sGPs). In the atrium, 5 sGPs were identified: (1) the ventral right atrial sGP, which covers the ventral superior RA, the ventral side of the root of the SVC, and the ventral inferior RA; (2) the
Anatomical localization of the major left atrial ganglionated plexi. Posterior view of the left and right atria displaying the presumed location of the major atrial ganglionated plexi (GPs) and the ligament of Marshall (LOM). The SLGP is located on the roof of the left atrium (LA), near the LSPV-LA junction; the ILGP is situated at the inferior aspect of the posterior wall of the LA; the ARGP is located anterior to the RSPV; the IRGP is situated at the inferior aspect of the LA. The ILGP and the IRGP are normally located ~3 cm below the lower edge of the inferior pulmonary veins. SLGP, superior left GP; ILGP, inferior left GP; ARGP, anterior right GP; IRGP, inferior right GP; LSPV, left superior pulmonary vein; LIPV, left inferior pulmonary vein; RSPV, right superior pulmonary vein; RIPV, right inferior pulmonary vein; CS, coronary sinus; SVC, superior vena cava; IVC, inferior vena cava.

Although different classifications exist for the identification of atrial GPs, there is considerable anatomical overlap between them (Table 1).

The innervation of the sinus node (SN) and the atrioventricular node (AVN) is mediated by different GPs (30). The SN is primarily regulated by the ventral and dorsal right atrial sGPs (corresponding to the anterior right GPs), whereas the AVN is supplied by fibers originating from the left dorsal, middle dorsal, ventral right, and dorsal right sGPs, extending toward the interatrial septum (corresponding to the inferior right GP).

Another component of the ICNS is represented by the ligament of Marshall (LOM), which is a developmental vestige of the embryonic left SVC, described by John Marshall in 1850 (31). This structure is innervated by predominantly parasympathetic fibers, which originate from the left vagus, travel through the LOM, and innervate surrounding left atrial structures, including the PVs, left atrial appendage, coronary sinus, and posterior left atrial fat pad. The vagal effects mediated by the LOM in the left atrium provide the basis for its arrhythmogenic role in the genesis and maintenance of AF (32).
Pathophysiology of atrial fibrillation: The role of the autonomic nervous system

Pathophysiology of AF results from a complex interplay between triggers (3), drivers (33), and substrate (34). In this context, the autonomic nervous system can modulate different components of atrial cellular electrophysiology inducing and sustaining AF (35). Animal studies demonstrated that all AF episodes are preceded by the activation of the ICNS and that its ablation can reduce atrial vulnerability, thus suggesting the importance of the ICNS in AF arrhythmogenesis (36, 37).

PVs are a known source of AF triggers due to the short action potential duration (APD) of PV cells, the APD gradient at the PVs-LA junction, and the short coupling interval for excitation (38). Therefore, excitation during repolarization, or early after depolarizations (EADs), is the result of the typical electrophysiological characteristics of PV cells. In canine PVs preparations, pacing-induced EADs were able to generate only rare single beats and never repetitive rhythms when exposed only to catecholamines. With combined exposition to catecholamines and acetylcholine, pacing-induced EADs were able to provoke rapid firing from PVs (39). This finding suggests a role of both sympathetic and parasympathetic effects in AF initiation. Sympathetic tone enhances the Ca_{2+} transient, characterized by an increase in calcium entry, storage, and release in the heart (40). Parasympathetic activity is mediated by the activation of the acetylcholine-activated potassium channel (I_{K-Ach}), which decreases the APD (39). The final combined result promotes the development of late phase 3 EAD-induced triggered activity in the atria and the PVs (41).

Furthermore, parasympathetic stimulation induces a significant increase in the heterogeneity of the atrial effective refractory period (ERP) (42), which may allow multiple-circuit reentry by reducing minimum circuit size and allowing more circuits to be accommodated in the atria (34).

The autonomic nervous system may play a role in arrhythmogenesis also inducing atrial electrical remodeling, thus contributing to AF perpetuation. In animal models, rapid atrial pacing (RAP) simulating AF was able to induce electrical remodeling, characterized by a progressive reduction of ERP, progressive increase in ERP dispersion, and enhanced AF inducibility. This electrical remodeling induced by RAP could be prevented by GPs ablation or autonomic pharmacological blockade with atropine and propranolol (43). RAP could also induce autonomic remodeling, characterized by increased parasympathetic and sympathetic activity, which was able to further enhance electrical remodeling, therefore creating a vicious cycle causing AF perpetuation (“AF begets AF”) (44).

Thus, the elimination of adrenergic and cholinergic fibers within GPs might improve outcomes in patients with AF. The coexistence of adrenergic and cholinergic fibers in the GPs renders it nearly impossible to selectively ablate their adrenergic or cholinergic component. However, the anatomical distribution of the parasympathetic postganglionic neuronal bodies in the epicardial GPs makes parasympathetic reinnervation after ablation less likely (45).

### Autonomic denervation during cryoballoon catheter ablation for atrial fibrillation

**Principles of autonomic denervation with cryoballoon ablation**

The presence of atrial GPs hyperactivity has been demonstrated before episodes of AF on animal models (36), but the exact extent of these “hyperactive” GPs is still unknown. Three techniques have been described to localize and target autonomic GPs: (1) the anatomic approach, which relies on GPs ablation at their presumed anatomical locations (14), (2) high-frequency stimulation (HFS; 20 Hz, 10–150 V, pulse width 1–10 ms for 2–5 s), which relies on the identification of HFS-evoked vagal responses (≥50% increase in mean R-R interval during AF) to differentiate GPs from atrial myocardium (27), and (3) electrogram analysis, to identify fragmented atrial potentials. Using fast Fourier transformation, Pachon...
et al. (45) defined compact and fibrillar atrial potentials during sinus rhythm and postulated that fragmented fibrillar atrial potentials were the markers of GPs insertion in the atrial tissue. Furthermore, the presence of at least four deflections in the signal at the ablation site has been demonstrated to be the best predictor of a vagal response during RF ablation (46).

HFS-induced vagal response has proven to be a specific but not sensitive method to target the GPs, probably due to the limited effect of the endocardial stimulation of the GPs which are located epicardially (27). Furthermore, despite its theoretical principle, RF ablation of GPs based on HFS has not been demonstrated to be superior to the anatomic approach (47). One postulated explanation is related to the wider ablation area in the anatomic approach compared to the HFS-based strategy, suggesting better results with more extensive regional ablation. Another possible explanation might be the relatively small anatomical variations of the main left atrial GPs, which lie close to the PV-left atrial junction.

These findings explain the rationale for the possible concomitant neuromodulation during CB-A for AF. PVI with CB-A, especially with the 28-mm CB catheter, is associated with a broad antral ablation area that extends from the PV ostium toward the LA (17, 18), thus increasing the possibility of concomitant and extended GPs ablation (19). Compared to RF-A, PVI with CB-A has been demonstrated to involve a wider surface of the ICNS (18). Common antral PVI with RF-A is typically characterized by concomitant transection of two of the four GPs (i.e., ARGP and SLGP) since the inferior GPs are typically distant from the inferior edge of the usual antral isolation area (27). CB-A of PVs with the 28-mm CB catheter, instead, can simultaneously affect all the major GPs, possibly including the hyperactive GPs, with a higher effect on the SLGP and ARGP and a smaller involvement of the ILGP, likely due to its anatomical variations (20). Indeed, a vagal response has been observed in 38.3% of the patients undergoing PVI with CB-A (48), while it has been reported only in 17% of patients during RF-A, mostly during ablation of the left PVs (49).

**Assessment of neuromodulation during cryoballoon ablation for atrial fibrillation**

The effect of CB-A on the ICNS can be assessed both in the acute phase after PVI (i.e., intraoperatively or within 24 h after PVI) and in the longer term (after the first 24 h post-PVI) (Table 2).

In the acute phase, neuromodulation during CB-A may be demonstrated intraoperatively with the occurrence of a vagal reaction, defined as sinus bradycardia <40 bpm, asystole, atrioventricular block, or hypotension, which has been described during balloon thawing and balloon deflation in 40.7% of patients (19). Moreover, neuromodulation during PVI with CB-A can be assessed 24 h after PVI with an increase in heart rate (HR) and with a lowering in systolic blood pressure increase during the handgrip test (51). HR increase after PVI has been significantly associated with: age at ablation, baseline heart rate before CB-A, and nadir temperature in each right PV (53).

A method to reliably quantify the acute degree of vagal denervation is extracardiac vagal stimulation (ECVS) (54). In brief, a quadripole catheter is advanced through the right femoral vein to the right internal jugular vein in the region of the jugular foramen, directed medially. Usually, in this place, there is proximity to the vagus nerve. ECVS is obtained by a pulsed...
Del Monte et al. /one.tnum/zero.tnum./three.tnum/three.tnum/eight.tnum/nine.tnum/fcvm./two.tnum/zero.tnum/two.tnum/two.tnum./nine.tnum/five.tnum/eight.tnum/three.tnum/one.tnum/six.tnum

FIGURE /two.tnum
Extracardiac vagal stimulation during cryoballoon ablation. (A) Anteroposterior fluoroscopic view of a quadripolar catheter advanced through the right jugular vein to the jugular foramen for vagal stimulation. (B) Example of cryoballoon ablation of the right superior pulmonary vein (anteroposterior fluoroscopic view). (C) Extracardiac vagal stimulation before PVI showing a marked vagal response (asystole of around 14 s) followed by atrial fibrillation induction. (D) Extracardiac vagal stimulation at the end of cryoballoon ablation showing the absence of a vagal response (RR interval changes from 834 to 868 ms).

electric field (pulse amplitude of 0.5–1 V/kg body weight up to 70 V, 50 ms pulse width, 50 Hz frequency, lasting 5 s) within the jugular vein to elicit a vagal response. The typical response is transitory sinus arrest or bradycardia, defined as prolongation of the RR interval by >50%, and/or atrioventricular block. ECVS is performed before and after PVI, and neuromodulation is confirmed if a reduction in the vagal response is achieved (Figure 2). In all patients with paroxysmal AF undergoing PVI with CB-A, ECVS demonstrated a varying degree of parasympathetic denervation, and ablation of the RSPV has been associated with the most significant acute reduction of parasympathetic tone (55). This response has proven to be more sensitive in quantifying vagal denervation than the increase in heart rate (50).

The longer-term (>24 h after PVI) effect of CB-A on vagal denervation has been described using HR and Heart Rate Variability (HRV), as surrogates for GPs modulation. Oswald et al. (52), who were the first to investigate the effect of CB-A on the ICNS, demonstrated that in the majority of patients CB-A was associated with significant changes in HRV during follow-up. Furthermore, in a cohort of 103 patients undergoing PVI with the 28-mm second-generation CB catheter, increased HR persisted in 37.9% of patients even at 12 months after PVI (56).

Prognostic impact of neuromodulation with cryoballoon ablation for atrial fibrillation

Numerous studies investigated the role of neuromodulation associated with CB-A of PVs on AF outcome (Table 3).

In patients with persistent AF, the occurrence of an intraprocedural vagal reaction, defined as bradycardia <40 beats/min, asystole, or high-degree atrioventricular block, was an independent predictor of AF-free survival after PVI with CB-A (58). Comparable results were confirmed also in patients with
TABLE 3  Summary of the principal studies investigating the role of neuromodulation with cryoballoon ablation on atrial fibrillation outcome.

| References          | N. of patients | Type of AF | Type of CB | Neuromodulation assessment | Follow-up | Effect on AF outcome |
|---------------------|----------------|------------|------------|----------------------------|-----------|----------------------|
| Oswald et al. (52)  | 14             | Paroxysmal | Arctic Front, 28 mm VR* during CB-A, HRV during follow-up | 3 months | No association with AF recurrence |
| Yorgun et al. (19)  | 145            | Paroxysmal (n = 117) and persistent (n = 28) | Arctic Front, 28 mm VR* during CB-A | 17 (4–27) months | VR was more common in patients without AF recurrence (46.2% vs. 15.4%, P = 0.004); VR requiring atropine or temporary pacing was an independent predictor of AF-free survival (HR 0.064; 95% CI 0.008–0.48, p = 0.008) |
| Aytemir et al. (57) | 306            | Paroxysmal (n = 247) and persistent (n = 59) | Arctic Front, 28 mm (n = 197) and Arctic Front Advance, 28 mm (n = 109) VR* during CB-A | 22 (13–34) months | VR was a predictor of AF-free survival (HR 0.550, 95% CI 0.331–0.915, p = 0.021) |
| Miyazaki et al. (56) | 103            | Paroxysmal | Arctic Front Advance, 28 mm | 15.0 (12.0–18.0) months | No association with AF recurrence (p = 0.300 and p = 0.224, respectively) |
| Te et al. (16)      | 39             | Paroxysmal | Arctic Front Advance, 28 mm | 14 ± 6 months | Increased AF-free survival of patients with VR compared to patients without VR (log rank p = 0.006) |
| Guzek et al. (58)   | 250            | Persistent | Arctic Front Advance, 28 mm | 12 months | VR was an independent predictor of AF-free survival (HR 0.11; 95% CI 0.03–0.34; p < 0.01) |
| Maj et al. (53)     | 472            | Paroxysmal (n = 459) and persistent (n = 13) | Arctic Front Advance Pro, 28 mm | HR increase >15 bpm after CB-A compared to baseline | 27.7 ± 12.5 months | Patients with HR increase >15 bpm presented higher AF-free survival (83.1% vs. 66.3%, respectively; Log Rank p = 0.021) |
| Giliburean et al. (59) | 110, CB-A n = 71 and persistent (n = 38) | Paroxysmal (n = 72) | Arctic Front Advance Pro, 28 mm | DC on ECG Holter after CB-A | 15.4 (7.0–28.2) months | Higher DC was an independent predictor of AF recurrence (HR 1.68, 95% CI 1.35–1.92, p = 0.004) |
| Tang et al. (60)    | 346, CB-A n = 231 | Paroxysmal | Arctic Front Advance, 23- or 28-mm | HR increase after CB-A measured with ICM | 12 months | Patients without AF recurrence presented faster daytime (11 ± 11 vs. 8 ± 12 bpm, p = 0.001) and nighttime HR (8 ± 9 vs. 6 ± 8 bpm, p = 0.049) compared to patients with AF recurrence |

AF, atrial fibrillation; CB, cryoballoon; CB-A, cryoballoon ablation; VR, vagal reaction; HR, heart rate; HRV heart rate variability; HR, hazard ratio; CI, confidence interval; DC, deceleration capacity; ICM, implantable cardiac monitor.

*Sinus bradycardia (heart rate < 40 bpm), asystole, complete atrioventricular block, or hypotension (systolic blood pressure < 90 mm Hg, diastolic blood pressure < 60 mm Hg or a sudden drop in blood pressure from baseline by at least 20 mm Hg).

Furthermore, high parasympathetic activity after RF-A and CB-A of PVs has been associated with AF recurrence. An HR increase ≥15 bpm after CB-A compared to pre-PVI could stratify patients with a higher AF-free survival at a 2-years follow-up (53). Similarly, Tang et al. (60) observed that daytime and nighttime heart rates were significantly higher in paroxysmal AF undergoing CB-A (16, 57). In this population, the occurrence of vagal reactions during PVI was associated with an inferior rate of AF recurrence in the mid-term. Similarly, an intraprocedural vagal reaction requiring atropine administration or temporary pacing decreased the risk of AF recurrence (19).
patients without AF recurrence, compared to patients with AF recurrence. Moreover, high deceleration capacity (DC) at ECG Holter monitoring could predict AF recurrence after PVI with CB-A (59). Interestingly, high parasympathetic tone, expressed by DC and other surrogate markers, could predict not only AF recurrence but also PV reconnection (61). Right-sided only PVs reconnection was associated with higher parasympathetic tone than left-sided only PVs reconnection. This might be explained by a suboptimal lesion created during CB-A, with associated incomplete PVI and preserved function of GPs in the region of reconnected PVs. In particular, suboptimal lesions on right-sided PVs are associated with higher persistence of parasympathetic tone because of the preserved function of the ARGP, which represents the final common parasympathetic pathway to the SN.

Despite these results, other authors failed to prove any positive clinical correlation between autonomic modulation and AF recurrence after CB-A. In one study analyzing 103 patients with paroxysmal AF undergoing PVI with the 28-mm second-generation CB catheter, neither intra-procedural vagal reactions nor HR increase could predict AF recurrence (56).

Direct comparative data on RF-A vs. CB-A of GPs on AF outcome is scarce; however, some evidence suggests that no significant difference exists between the two ablation strategies (60, 62).

Along with its beneficial effect on AF outcome, GPs ablation has also been associated with a potential proarrhythmic effect. With RF-A, GPs ablation added to PVI has been reported to carry a higher risk of ablation-induced left atrial tachycardias than PVI alone, mostly due to the creation of supplemental atrial lesions (27). Selective anatomic or HFS-mediated radiofrequency GPs ablation has been complicated by atrial macroreentry in 2–10% of patients (14). A notably increased proarrhythmic risk has been described in animal models with selective GPs ablation without PVI, likely secondary to a decreased atrial ERP and a hyper-reinnervation of both sympathetic and parasympathetic nerves after 8 weeks (63). However, with CB-A, neuromodulation is a concomitant effect obtained during PVI, and no additional applications are delivered to selectively target the GPs. Therefore, the proarrhythmic effect related to concomitant neuromodulation during CB-A is the one related to PVI with the cryoballoon (64, 65), which may cause an increased heterogeneity of refractoriness within the atria.

### Discussion and future perspectives

The significant role of the ICNS in the initiation and maintenance of AF is well-known, however conflicting results still exist regarding the association between autonomic modulation during PVI with CB-A and AF outcome. The explanation of this phenomenon may be multifactorial.

First, adequate patient selection might play a major role in the additional benefit of neuromodulation on AF recurrence. Although GPs ablation has demonstrated additional benefits when associated with PVI in paroxysmal AF, the results of the AFABT study (66) demonstrated that GPs ablation during thoracoscopic surgical ablation of advanced AF had no beneficial effect on AF recurrence. This evidence may suggest that the therapeutic advantage of GPs ablation is more evident at an earlier stage of AF when the role of the ICNS in AF initiation and perpetuation is more significant.

Second, the use in the literature of different markers of autonomic modulation (e.g., vagal reaction, HR, and HRV) to evaluate the impact of autonomic denervation on AF recurrence limits the comparison between studies for outcome analysis. Furthermore, vagal reactions, HR increase, and decreased HRV may be imprecise in reflecting complete vagal denervation. The adoption of a standardized approach, like the ECVS, to assess vagal denervation after PVI may allow more reliable data on the real incidence and clinical significance of complete vagal denervation with CB-A. However, future studies are needed to support this theory.

Third, a potential limitation of the effect of neuromodulation on AF outcome in the long-term is the possible occurrence of reinnervation post-PVI, as already reported after both surgical excision and RF-A of GPs (67, 68). Prior studies on CB-A with the first-generation CB showed that autonomic modulation expressed as increased HR and decreased HRV, recovered after 3–6 months post-PVI (52). More recent evidence on CB-A with the second-generation CB reported a persistent effect on neuromodulation up to 12 months post-PVI (56). This difference might be explained by the more extensive ablation lesion created by the second-generation CB, which may cause destruction not only of nerve axons but also of nerve cell bodies. Similar durable effects of neuromodulation have also been described with RF-A (69).

Finally, autonomic modulation with CB-A is a concomitant effect obtained during PVI. Despite the evidence of a wide ablation area created by the CB catheter, GPs ablation during PVI may be incomplete in some cases, thus reducing its beneficial effect or increasing the arrhythmic risk. Only recently, different mapping systems, like the dielectric imaging and navigation system (KODEX-EPD™; EPD Solutions, Philips, Eindhoven, The Netherlands), have been developed to allow the visualization of the multipolar mapping catheter used during CB-A to facilitate the procedure (70). Future research in this field may focus on the implementation of those mapping systems (e.g., refined electrogram analysis) to precisely target the GPs and achieve complete GPs ablation during PVI with CB-A or perform selective neuromodulation with the CB catheter.

Besides RF-A and CB-A, new energy sources are available for the treatment of AF (71). Among them, pulsed-field ablation (PFA) is emerging as a promising non-thermal ablation modality that creates lesions through irreversible electroporation. One
of the main advantages of PFA is its theoretical superior safety profile related to tissue selectivity for cardiac tissue, with no or minimal effects on adjacent structures (72). Animal studies demonstrated the preservation of pheic nerve and esophageal tissue despite exposure to clinical PFA energies (73, 74). However, currently, no clinical data is available on the effect of PFA on the ICNS, and future studies are needed to determine its role in neuromodulation during AF ablation.

Conclusion

Due to the anatomical proximity of the main left atrial GPs with the PVs and the characteristics of the CB, neuromodulation is a common concomitant effect obtained during PVI with CB-A. Although some evidence supports this theory, the real additional beneficial effect of neuromodulation during CB-A on AF outcome has still not been completely clarified.

Author contributions

ADM and LP searched and analyzed the literature. ADM wrote the manuscript. LP, AB, and GBC reviewed and edited the manuscript. All authors have read and approved the final manuscript.

Conflict of interest

Author AB is consultant for Biotronik. Author GBC received compensation for teaching purposes and procuring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. Author CdA receives research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, Acutus Medical, and received compensation for teaching purposes and procuring from Medtronic, Abbott, Biotronik, LivaNova, Boston Scientific, AtriCure, Acutus Medical, and Daiichi Sankyo.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quinio G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins New England J Med (1998) 339:659-66. doi: 10.1056/NEJM199809033390605
2. Lin WS, Tai CT, Hsieh MH, Tsai CE, Lin YK, Tsao HM, et al. Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy. Circulation. (2003) 107:3176–83. doi: 10.1161/01.CIR.0000107426.52052.D2
3. Della Rocca DG, Tarantino N, Trivedi C, Mohanty S, Ananah A, Salwan AS, et al. Non-pulmonary vein triggers in nonparoxysmal atrial fibrillation: implications of pathophysiology for catheter ablation. J Cardiovasc Electrophysiol. (2020) 31:2154–67. doi: 10.1111/jce.14638
4. Hindricks G, Potpara T, Dagnos N, Bas JJ, Borzani G, Dan GA, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. (2021) 42:373–498. doi: 10.1093/eurheartj/ehab648
5. Kuck KH, Brugada J, Furrkranz A, Metzner A, Ouyang F, Chun I, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. (2016) 374:2235–45. doi: 10.1056/NEJMoa1602014
6. Lim PB, Malcolm-Lawes LC, Stuber T, Wright I, Francis DP, Davies DW, et al. Intracardiac cardiac autonomic stimulation induces pulmonary vein ectopy and triggers atrial fibrillation in humans. J Cardiovasc Electrophysiol. (2011) 22:638–46. doi: 10.1111/j.1540-8167.2010.01992.x
7. Lim PB, Malcolm-Lawes LC, Stuber T, Kojo-dejojo P, Wright IJ, Francis DP, et al. Stimulation of the intrinsic cardiac autonomic nervous system results in a gradient of fibrillatory cycle length shortening across the atria during atrial fibrillation in humans. J Cardiovasc Electrophysiol. (2011) 22:1224–31. doi: 10.1111/j.1540-8167.2010.02097.x
8. Bettini M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation. (2002) 105:2753–9. doi: 10.1161/01.CIR.0000018443.44005.D8
9. Tomita T, Takei M, Saikawa Y, Hanaoka T, Uchikawa SI, Tsutsui H, et al. Role of autonomic tone in the initiation and termination of paroxysmal atrial fibrillation in patients without structural heart disease: J Cardiovasc Electrophysiol. (2003) 14:559–64. doi: 10.1046/j.1540-8167.2003.02462.x
10. Ardell JL, Armour JA. Neurocardiology: structure-based function. Compr Physiol. (2016) 6:1635–53. doi: 10.1002/cphy.c150046
11. Tan AY, Li H, Wachsmann-Hogiu S, Chen LS, Chen PS, Fushibein MC. Autonomic innervation and segmental muscular disconnections at the human pulmonary vein-atrial junction. Implications for catheter ablation of atrial-pulmonary vein junction. J Am Coll Cardiol. (2006) 48:132–43. doi: 10.1016/j.jacc.2006.02.054
12. Pappone C, Santinelli V, Manguo F, Vicedomini G, Gugliotta F, Angello G, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. (2004) 109:327–34. doi: 10.1161/01.CIR.0000126411.16340.C7
13. Zhang Y, Wang Z, Zhang Y, Wang W, Wang J, Gao M, et al. Efficacy of cardiac autonomic denervation for atrial fibrillation: a meta-analysis. J Cardiovasc Electrophysiol. (2012) 23:592–600. doi: 10.1111/j.1540-8167.2011.02270.x
14. Katritsis DG, Pokushalov E, Romanov A, Gizanoglou E, Siontis GCM, Po SS, et al. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol. (2013) 62:2318–25. doi: 10.1016/j.jacc.2013.06.053
15. Ahmed H, Neuzil P, Skoda J, D’Avila A, Donaldson DM, Laragy MC, et al. The permanency of pulmonary vein isolation using a balloon cryoahteter. J Cardiovasc Electrophysiol. (2010) 21:731–7. doi: 10.1111/j.1540-8167.2009.01703.x
16. Te ALO, Lo LW, Lin YJ, Chang SL, Hu YE, Chung FP, et al. Vasovagal responses during cryoballoon pulmonary vein isolation in paroxysmal atrial fibrillation predict favorable mid-term outcomes. Int J Cardiovasc. (2018) 258:115–20. doi: 10.1016/j.ijcard.2018.01.111
17. Chierchia GB, de Asmundis C, Sorgente A, Paparella G, Sarkozy A, Muller-Burri SA, et al. Anatomical extent of pulmonary vein isolation after cryoballoon
57. Aytemir K, Gurses KM, Yalcin MU, Kocygjt D, Dural M, Evranos B, et al. Safety and efficacy outcomes in patients undergoing pulmonary vein isolation with second-generation cryoballoon. Europace. (2015) 17:379-87. doi: 10.1093/europace/eua273

58. Guckel D, Schmidt A, Gutleben KJ, Körber B, Fischbach T, Horsnitote D, et al. Pulmonary vein isolation and beyond: Predictive value of vagal reactions in second-generation cryoballoon ablation for the outcome of persistent atrial fibrillation. Heart Rhythm. (2020) 17:600-6. doi: 10.1016/j.hrthm.2019.12.006

59. Călburean PA, Osório TG, Sieira J, Ströker E, Maj R, Terasawa M, et al. High parasympathetic activity as reflected by deceleration capacity predicts atrial fibrillation recurrence after repeated catheter ablation procedure. J Interven Card Electrophysiol. (2021) 60:21–9. doi: 10.1007/s10840-019-00687-9

60. Tang LYW, Hawkins NM, Ho K, Tam R, Deyell MW, Macle I, et al. Autonomic alterations after pulmonary vein isolation in the circa-dose (Cryoballoon vs. irrigated radiofrequency catheter ablation) study. J Am Heart Assoc. (2021) 10:e118610. doi: 10.1161/JAHA.120.018610

61. Călburean PA, Osorio TG, Sorgente A, Almorad A, Pannone L, Monaco C, et al. High vagal tone predicts pulmonary vein reconnection after cryoballoon ablation for paroxysmal atrial fibrillation. PACE Pacing Clin Electrophysiol. (2021) 44:2075–83. doi: 10.1111/pace.14408

62. Takahashi K, Watanabe I, Okumura Y, Nagashima K, Watanabe R, Arai M, et al. Effect of cryoballoon ablation vs. radiofrequency ablation on left atrial ganglionated plexi in patients with atrial fibrillation. J Nihon Univ Med Assoc. (2018) 77:87–91. doi:10.4264/numa.77.2_87

63. Mao J, Yin X, Zhang Y, Yan Q, Dong J, Ma C, et al. Ablation of epicardial ganglionated plexi increases atrial vulnerability to arrhythmias in dogs. Circ Arrhyth Electrophysiol. (2014) 7:711–7. doi:10.1161/CIRCEP.113.000799

64. Mukhaylov EN, Bhagwandien R, Janse PA, Theuns DAMJ, Szili-Torok T. Regular atrial tachycardias developing after cryoballoon vein isolation: incidence, characteristics, and predictors. Europace. (2013) 15:1710-7. doi: 10.1093/europace/eut129

65. Julià J, Chierchia GB, de Asmundis C, Mugnai G, Sieira J, Ciconte G, et al. Regular atrial tachycardias following pulmonary vein isolation for paroxysmal atrial fibrillation: a retrospective comparison between the cryoballoon and conventional focal tip radiofrequency techniques. J Intervent Card Electrophysiol. (2015) 42:161-9. doi: 10.1007/s10840-014-9961-4

66. Driessen AHG, Berger WR, Krul SJ, van den Berg NWE, Neefs J, Piersma FR, et al. Ganglion plexus ablation in advanced atrial fibrillation: the AFACT study. J Am Coll Cardiol. (2016) 68:1155–65. doi: 10.1016/j.jacc.2016.06.036

67. Sakamoto S-i, Schuesseler RB, Lee AM, Aziz A, Lall SC, Damiano RJ. Vagal denervation and reinnervation after ablation of ganglionated plexi. J Thor Cardiovasc Surg. (2010) 139:444–52. doi: 10.1016/j.jtcvs.2009.04.056

68. Wang X, Zhang M, Zhang Y, Xie X, Wang W, Li Z, et al. Long-term effects of ganglionated plexi ablation on electrophysiological characteristics and neuron remodeling in target atrial tissues in a canine model. Circ Arrhyth Electrophysiol. (2015) 8:1276–83. doi: 10.1161/CIRCEP.114.002554

69. Pachon EL, Santillana-P TG, Lobo TJ, Pachon-M JC, Zerpa-A JC, Cunha-P MZ, et al. Long-term evaluation of the vagal denervation by cardioneuroablation using bolter and heart rate variability. Circ Arrhyth Electrophysiol. (2020) 13:e008703. doi: 10.1161/CIRCEP.120.008703

70. Rottner L, Nodorp M, Jessica W, Schleberger R, Sinning C, Lemoine M, et al. High anatomical accuracy of a novel high-resolution wide-band dielectric imaging system in cryoballoon-based ablation. PACE Pacing Clin Electrophysiol. (2021) 44:1504–15. doi: 10.1111/pac.14324

71. Verma MS, Terricabras M, Verma A. The cutting edge of atrial fibrillation ablation. Arthrhyth Electrophysiol Rev. (2021) 10:101–7. doi: 10.15420/aer.2020.40

72. Bradley CJ, Haines DE. Pulsed field ablation for pulmonary vein isolation in the treatment of atrial fibrillation. J Cardiovasc Electrophysiol. (2020) 31:2136–47. doi: 10.1111/jce.14414

73. Neven K, van Es B, van Driel V, van Wessel H, Fidder H, Vink A, et al. Acute and long-term effects of full-power electroporation ablation directly on the porcine esophagus. Circ Arrhyth Electrophysiol. (2017) 10:e004672. doi: 10.1161/CIRCEP.116.004672

74. van Driel VBEM, Neven K, van Wessel H, Vink A, Doervendans PAFM, Wittkampf FHM. Low vulnerability of the right phrenic nerve to electroporation ablation. Heart Rhythm. (2015) 12:1838–44. doi: 10.1016/j.hrthm.2015.05.012